94 related articles for article (PubMed ID: 5110668)
21. Chemotherapy in the treatment of ovarian cancer. (the cancer-chemotherapy-sensitvity-test).
Limburg H
Nihon Sanka Fujinka Gakkai Zasshi; 1969 Aug; 21(8):907-8. PubMed ID: 5388529
[No Abstract] [Full Text] [Related]
22. Cell cultures and their use in drug sensitivity prediction.
Dendy PP; Mitchell JS; Dawson A; Williamson J
Arch Geschwulstforsch; 1981; 51(1):111-8. PubMed ID: 7259433
[TBL] [Abstract][Full Text] [Related]
23. [Potentiation of the antitumor activity of dioxadet by antiestrogen para-aminobenzhydrazide in a model of ovarian ascites tumor].
Tret'iakov AV; Kraĭz BO
Vopr Onkol; 1983; 29(12):66-8. PubMed ID: 6666098
[TBL] [Abstract][Full Text] [Related]
24. Ovarian cancer and its treatment.
Grönroos M; Laurén P; Lehto J; Rauramo L
Ann Chir Gynaecol Fenn; 1969; 58(2):83-9. PubMed ID: 5363960
[No Abstract] [Full Text] [Related]
25. [Sensitivity of neoplastic cells to cytostatics in vitro].
Andrysek O
Cas Lek Cesk; 1972 Nov; 111(45):1063-4. PubMed ID: 5084858
[No Abstract] [Full Text] [Related]
26. [Use of different methods for the primary selection of antitumor antibiotics].
Ivanitskaia LP; Upiter GD
Antibiotiki; 1967 May; 12(5):369-74. PubMed ID: 5627678
[No Abstract] [Full Text] [Related]
27. [Effect of cytostatics on explants of human ovarian cancer].
Schleich A
Arch Gynecol; 1979 Jul; 228(1-4):437. PubMed ID: 485418
[No Abstract] [Full Text] [Related]
28. VEGF expression and the effect of NSAIDs on ascites cell proliferation in the hen model of ovarian cancer.
Urick ME; Giles JR; Johnson PA
Gynecol Oncol; 2008 Sep; 110(3):418-24. PubMed ID: 18606441
[TBL] [Abstract][Full Text] [Related]
29. [The possibility of selective chemotherapy of progressive recurring ovarian carcinoma with the aid of cytodiagnosis and incorporation of tagged idoxuridine].
Dvorák O; Andrýsek O; Stránská E
Geburtshilfe Frauenheilkd; 1969 Jul; 29(7):648-53. PubMed ID: 5799686
[No Abstract] [Full Text] [Related]
30. Chemotherapy in ovarian malignancy: tumor sensitivity testing.
Riggs JA; Jackson LG; Weiss AJ; Farell DM; Traiman R
Obstet Gynecol; 1966 Jun; 27(6):869-74. PubMed ID: 5327493
[No Abstract] [Full Text] [Related]
31. Short-term cultures of clinical tumor material: potential contributions to oncology research.
Baguley BC; Marshall ES; Finlay GJ
Oncol Res; 1999; 11(3):115-24. PubMed ID: 10527071
[TBL] [Abstract][Full Text] [Related]
32. The medical-surgical nurse's guide to ovarian cancer: Part II.
Bohnenkamp S; LeBaron V; Yoder LH
Medsurg Nurs; 2007 Oct; 16(5):323-31; quiz 332. PubMed ID: 18072671
[No Abstract] [Full Text] [Related]
33. Biochemical blood studies in patients with carcinoma of the ovaries during treatment with preparation C-283. II. Behavior of seromucoid and its electrophoretic fractions.
Gerber J; Osada J; Jabłoński K; Dobryszycka W
Arch Immunol Ther Exp (Warsz); 1972; 20(1):139-47. PubMed ID: 4621186
[No Abstract] [Full Text] [Related]
34. [The problem of accidental paravenous application of cytostatics--case history (author's transl)].
Sommer H; Meinhold P
Zentralbl Gynakol; 1981; 103(21):1324-8. PubMed ID: 6798785
[TBL] [Abstract][Full Text] [Related]
35. Influence of catumaxomab on tumor cells in bone marrow and blood in ovarian cancer.
Wimberger P; Heubner M; Lindhofer H; Jäger M; Kimmig R; Kasimir-Bauer S
Anticancer Res; 2009 May; 29(5):1787-91. PubMed ID: 19443405
[TBL] [Abstract][Full Text] [Related]
36. [Our experiences with cytostatics in cases of malignant ovarian tumors].
Ferkó S; Gál I; Szönyi I
Orv Hetil; 1967 Mar; 108(11):496-8. PubMed ID: 6047073
[No Abstract] [Full Text] [Related]
37. [Correlation between ATP bioluminescence tumor chemosensitivity assay and clinical response in ovarian cancer].
Tian HM; Shi XY; Fu J; Chao DY; Zhang K; Wu LY; Wang JW; Zhang W
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):296-8. PubMed ID: 15996325
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapy for ovarian cancer.
Boronow RC; Bell WN
J Miss State Med Assoc; 1968 Nov; 9(11):515-9. PubMed ID: 5722884
[No Abstract] [Full Text] [Related]
39. A proposal to use CA-125 to evaluate activity of new antineoplastic agents in ovarian cancer.
Markman M
Gynecol Oncol; 1993 Dec; 51(3):297-8. PubMed ID: 8112634
[No Abstract] [Full Text] [Related]
40. [Sensitivity test of antineoplastic drugs by the fluorescein (FDA) diacetate method].
Futonaka H; Inoue M
Saishin Igaku; 1969 Aug; 24(8):1792-5. PubMed ID: 5358057
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
